|
|
|
|
 |
|
||
|
|||
 |
|
||
 |
 |
 |
|
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
March 5 , 2008
Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
FDA Also Grants Orphan Drug Status to Reslizumab for Pediatric EE
Ception Therapeutics, Inc. announced today the initiation of a multi-center, Phase II/III clinical trial to evaluate reslizumab, a humanized monoclonal antibody (mAb) against interleukin-5 (IL-5), for the treatment of eosinophilic esophagitis (EE) in pediatric patients. Read More>>
May 31 , 2007
Ception Therapeutics Raises Additional $14.7 Million Bringing Total Series C Financing to $77 Million
Ception Therapeutics, Inc., an emerging biopharmaceutical company discovering and developing novel biologic and small-molecule agents to address unmet medical needs, today announced that it has raised an additional $14.7 million, bringing the total of private equity raised this year through a Series C private placement of preferred stock to $77 million.
Read More>>
January 30, 2007
Ception Therapeutics Raises $63 Million in Series C Financing
Ception Therapeutics, Inc., an emerging biopharmaceutical company discovering and developing novel biologic and small-molecule agents to address unmet medical needs, today announced that it has raised $63 million through a Series C private placement of preferred stock. Read More>>
If you are a news organization inquiring about Ception's current activities, please contact us and a representative will assist you.
Thank you for your interest in Ception Therapeutics.
